Literature DB >> 23098453

Expression of endogenous hypoxia markers in vulvar squamous cell carcinoma.

Yu-Zhu Li1, Shu-Ling Li, Xia Li, Li-Jie Wang, Jiu-Ling Wang, Jia-Wen Xu, Zhi-Hong Wu, Li Gong, Xiao-Dan Zhang.   

Abstract

OBJECTIVE: To investigate the expression of endogenous hypoxia-related markers identified as being involved in vulvar squamous cell carcinoma (VSCC).
METHODS: We performed immunohistochemical staining of hypoxia-inducible factor-1α(HIF-1α), glucose transporter-1 (GLUT-1), carbonic anhydrase 9 (CA-9) and vascular endothelial growth factor (VEGF), on tissue sections of 25 VSCC patients, 10 vulvar intraepithelial neoplasia (VIN) patients and 12 healthy controls.
RESULTS: HIF-1α expression was found in all sections, with no significant difference between controls, VIN and VSCC sections (all P<0.05). Glut-1 expression was found in 25% of control, 90% of VIN and 100% of VSCC sections. A significant difference between control and VIN or VSCC was observed (all P<0.05), while no difference was found between VIN and VSCC sections (P>0.05). CA-9 expression was negative in control sections, but it was found in 30% of VIN sections and 52% of VSCC sections with strong staining. Similarly, CA-9 expression also showed obvious differences between controls and VIN or VSCC sections (all P<0.05). However, there was no significant difference between VIN and VSCC (P>0.05). There were only 25% of control sections with weak VEGF expression, while strong staining was found in about 60% of VIN sections and 25% of VSCC sections (all P<0.05). In addition, a difference was also found between VIN and VSCC sections (P<0.05).
CONCLUSION: Expression of endogenous hypoxia markers (HIF-1α, GLUT-1, CA-9 and VEGF) might be involved in the malignant progression of VSCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23098453     DOI: 10.7314/apjcp.2012.13.8.3675

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  [Establishment of a rat model of dimethylbenzanthracene-induced vulvar squamous intraepithelial lesions].

Authors:  Yijin Fan; Huajun Tang; Yao Liu; Chengzhi Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  Vulvar cancer: a review for dermatologists.

Authors:  Anastasiya Atanasova Chokoeva; Georgi Tchernev; Elena Castelli; Elisabetta Orlando; Shyam B Verma; Markus Grebe; Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2015-05-01

Review 3.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

Review 4.  Chinese Herbs Interfering with Cancer Reprogramming Metabolism.

Authors:  Zhangfeng Zhong; William W Qiang; Wen Tan; Haotian Zhang; Shengpeng Wang; Chunming Wang; Wenan Qiang; Yitao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-05       Impact factor: 2.629

5.  Primary tumor vascularity, HIF-1α and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact.

Authors:  Hari Prasad Dhakal; Jahn M Nesland; Mette Førsund; Claes G Trope; Ruth Holm
Journal:  BMC Cancer       Date:  2013-10-29       Impact factor: 4.430

6.  GLUT-1 expression is largely unrelated to both hypoxia and the Warburg phenotype in squamous cell carcinomas of the vulva.

Authors:  Arnulf Mayer; Marcus Schmidt; Alexander Seeger; André Franke Serras; Peter Vaupel; Heinz Schmidberger
Journal:  BMC Cancer       Date:  2014-10-12       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.